Trial Protocol: Communicating DNA-based risk assessments for Crohn's disease: A randomised controlled trial assessing impact upon stopping smoking

BMC Public Health

Volumn 11, Issue , 2011, Pages

  Whitwell, Sophia C L ^a   Mathew, Christopher G ^b   Lewis, Cathryn M ^b   Forbes, Alastair ^c   Watts, Sally ^b   Sanderson, Jeremy ^d   Hollands, Gareth J ^a   Prevost, A Toby ^a   Armstrong, David ^a   Kinmonth, Ann Louise ^e   Sutton, Stephen ^e   Marteau, Theresa M ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^d ST THOMAS HOSPITAL   (United Kingdom)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15;

ADOLESCENT; ADULT; ARTICLE; ATTITUDE TO HEALTH; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; HUMAN; NUCLEOTIDE SEQUENCE; PREVALENCE; PROSPECTIVE STUDY; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; SMOKING; SMOKING CESSATION; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; ATTITUDE TO HEALTH; CLINICAL PROTOCOLS; COLITIS, ULCERATIVE; CROHN DISEASE; DNA MUTATIONAL ANALYSIS; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; NOD2 SIGNALING ADAPTOR PROTEIN; PREVALENCE; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SMOKING; SMOKING CESSATION;

EID: 78651472040     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-11-44     Document Type: Article

References (27)

1. A vision for the future of genomics research: a blueprint for the genomic future. FS Collins (Pubitemid 36520032)
2. Predictive genetics in primary care: expectations for the motivational impact of genetic testing affects the importance family physicians place on screening for familial cancer risk. R Gramling J Nash K Siren L Culpepper, Genetics in Medicine 2003 5 172 175 10.1097/01.GIM.0000068986.03217.BB 12792425 (Pubitemid 37006286)
3. The heuristic-systematic model in its broader context. S Chen S Chaiken, Dual Process Theories in Social Psychology New York: Guilford Press, Chaiken S, Trope Y, 1999 73 96
4. Clinicians' guide to inflammatory bowel disease. A Forbes, London: Chapman & Hall 1998
5. Estimating risks of common complex diseases across genetic and environmental factors: the example of Crohn's disease. CM Lewis SCL Whitwell A Forbes J Sanderson CG Mathew TM Marteau, Journal of Medical Genetics 2007 44 689 694 10.1136/jmg.2007.051672 17660460 (Pubitemid 350155455)
6. Estimating the odds ratios of Crohn disease for the main CARD15/NOD2 mutations using a conditional maximum likelihood method in pedigrees collected via affected family members. L Pascoe H Zouali M Sahbatou J-P Hugot, European Journal of Human Genetics 2007 15 864 71 10.1038/sj.ejhg.5201839 17457368 (Pubitemid 47109046)
7. A meta-analysis of the role of smoking in inflammatory bowel disease. BM Calkins, Dig Dis Sci 1989 34 1841 54 10.1007/BF01536701 2598752 (Pubitemid 20018648)
8. Smoking cessation and the course of Crohn's disease: An intervention study. J Cosnes L Beaugerie F Carbonnel JP Gendre, Gastroenterology 2001 120 1093 1099 10.1053/gast.2001.23231 11266373 (Pubitemid 32246663)
9. Influence of Smoking on Colonic Gene Expression Profile in Crohn's Disease. OH Nielsen JT Bjerrum C Csillag FC Nielsen J Olsen, PLoS ONE 2009 4 6210 10.1371/journal.pone.0006210 19603079
10. A population-based case-control study of CARD15 and other risk factors in Crohn's disease and ulcerative colitis. SR Brant MH Wang P Rawsthorne M Sargent LW Datta F Nouvet YY Shugart CN Bernstein, American Journal of Gastroenterology 2007 102 313 23 10.1111/j.1572-0241.2006.00926.x 17100976 (Pubitemid 46160545)
11. New links to the pathogenesis of Crohn disease provided by genome-wide association scans. CG Mathew, Nature Reviews Genetics 2008 9 9 14 10.1038/nrg2203 17968351 (Pubitemid 350277296)
12. Genetic susceptibility testing in smoking-cessation treatment: One-year outcomes of a randomized trial. J Audrain NR Boyd J Roth D Main NF Caporaso C Lerman, Addictive Behaviors 1997 22 741 751 10.1016/S0306-4603(97)00060-9 9426791 (Pubitemid 27511994)
13. Incorporating biomarkers of exposure and genetic susceptibility into smoking cessation treatment: Effects on smoking-related cognitions, emotions, and behavior change. C Lerman K Gold J Audrain TH Lin NR Boyd CT Orleans B Wilfond G Louben N Caporaso, Health Psychology 1997 16 87 99 10.1037/0278-6133.16.1.87 9028818 (Pubitemid 127465956)
14. Incorporating genetic susceptibility feedback into a smoking cessation program for African-American smokers with low income. CM McBride G Bepler IM Lipkus P Lyna G Samsa J Albright D Santanu BK Rimer, Cancer Epidemiology, Biomarkers & Prevention 2002 11 521 528 (Pubitemid 34615158)
15. Familial hypercholesterolaemia screening in the Netherlands: Psychological and social consequences. MV Maarle, University of Amsterdam: Amsterdam 2003
16. Predictive genetic testing for Alzheimer's disease: Impact upon risk perception. TM Marteau S Roberts S LaRusse RC Green, Risk Analysis 2005 25 397 404 10.1111/j.1539-6924.2005.00598.x 15876213 (Pubitemid 40664366)
17. The impact of genetic testing for Crohn's Disease, risk magnitude and graphical format on motivation to stop smoking: an experimental analogue study. AJ Wright C Takeichi SCL Whitwell M Hankins TM Marteau, Clinical Genetics 2008 73 306 314 10.1111/j.1399-0004.2008.00964.x 18261131 (Pubitemid 351386990)
18. Recruiting first-degree relatives for prevention research: A comparison of clinician-led and proband-led methods of contact in Crohn's disease. E Reid A Forbes J Sanderson CG Mathew C Lewis TM Marteau, European Journal of Human Genetics 2007 14 1263 1268 10.1038/sj.ejhg.5201699 (Pubitemid 44804032)
19. Rapid detection of common CARD15 variants in patients with inflammatory bowel disease. RL Roberts RB Gearry ML Barclay MA Kennedy, Molecular Diagnosis 2004 8 101 105 10.2165/00066982-200408020-00004 15527324 (Pubitemid 39363464)
20. Smoking cessation and smoking patterns in the general population: a 1-year follow-up. R West A McEwen K Bolling L Owen, Addiction 2001 96 891 902 10.1046/j.1360-0443.2001.96689110.x 11399220
21. Outcome criteria in smoking cessation trials: proposal for a common standard. R West P Hajek L Stead J Stapleton, Addiction 2005 100 299 303 10.1111/j.1360-0443.2004.00995.x 15733243 (Pubitemid 40363436)
22. Illness representations: Theoretical foundations. H Leventhal Y Benyamini S Brownlees MA Diefenbach EA Leventhal L Patrick-Miller, Perceptions of health & illness Amsterdam: Harwood Academic Publishers, Petrie KJ, Weinman JA, 1997 19 46
23. Protection motivation theory. RW Rogers S Prentice-Dunn, Handbook of health behavior research i: Personal and social determinants New York: Kluwer Academic/Plenum Press, Gochman D, 1997 113 132
24. The theory of planned behavior. I Ajzen, Organizational Behavior and Human Decision Processes 1991 50 179 211 10.1016/0749-5978(91)90020-T
25. Feasibility of a national longitudinal study ('The Smoking Toolkit Study') to monitor smoking cessation and attempts at harm reduction in the UK. R West, 2006 http://www.smokinginengland.info/Ref/stp001.pdf
26. Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review. OC Ukoumunne MC Gulliford S Chinn JA Sterne PG Burney, Health Technology Assessment 1999 3 ii 92 10982317
27. Randomisation by cluster. Sample size requirements and analysis. A Donner N Birkett C Buck, American Journal of Epidemiology 1981 114 906 914 7315838